By Brazil Stock Guide – Brazil’s private-health regulator ANS is set to rule on Friday (Dec. 5), on an administrative appeal filed by Hapvida (B3: HAPV3) that could force the company to restate financial statements and reopen its 2024 results — an unusually severe step in the sector. The dispute centers on when the company recognized accounting effects from a debt-relief agreement under the federal Desenrola program, which granted Hapvida forgiveness of R$ 866 million owed to the public health system (SUS).
Disagreement Over Timing
ANS argues that Hapvida recognized an extraordinary gain of nearly R$ 900 million before the deal was formally completed by the government in late July 2025. Regulators say the gain should only have been booked after judicial deposits were offset or GRU payments were executed. The agency will examine three issues: the timing of recognition, the direct impact on earnings and market value, and the transparency and governance of the disclosures made to investors, according to Metrópoles.
What Desenrola Does
Desenrola is a federal program designed to regularize and settle historical debts between companies and the public sector, including obligations tied to SUS reimbursements (ReSUS) and ANS-related fines. Operators must formalize agreements with PGFN and ANS, setting values and the form of settlement, either through GRUs or judicial-deposit offsets.
For Hapvida, the program forgave R$ 866 million in SUS-related liabilities. The current dispute is not about the validity of the agreement itself but about when its effects could be recognized in financial statements: Hapvida booked the gain in 2024, while ANS maintains recognition would only be possible after settlement steps completed in 2025.
A Potentially Far-Reaching Revision
If ANS rejects the appeal, Hapvida will be required to republish all statements prior to the agreement’s effective date, including the entire 2024 fiscal year. That would eliminate the extraordinary gain, reopen numbers already disclosed to the market, and potentially trigger a case of regulatory non-compliance — a scenario that could force the company to raise capital from shareholders.
Company Response
Brazil Stock Guide requested comment from Hapvida but received no response by publication time. In its second-quarter earnings release, the company defended the accounting treatment adopted for the Desenrola agreement, stating that all effects were recognized in compliance with IFRS and validated by independent auditors. Hapvida said it adhered to and formalized the agreement with PGFN and ANS in December 2024 and recorded the respective accounting impacts after the structure of settlement was set.
According to the company, the dispute with ANS concerns only the timing of recognition. Hapvida argues that recording the gain in 2024 was appropriate, while the regulator believes it could only occur after judicial-deposit offsets or GRU payments completed in 2025. The firm maintains that the difference stems from a conceptual interpretation specific to the regulator and says it temporarily reversed the accounting effect only in the regulatory statements submitted to ANS, with no impact on the consolidated IFRS financials disclosed to investors.
Leave a Reply